Can a common anti-nausea medication also help treat early-onset alcoholism?

Can a common anti-nausea medication also help treat early-onset alcoholism?
Image: Intellect (generated)

In short: Ondansetron is best known for preventing vomiting after surgery or chemotherapy. Yet, researchers have discovered that this serotonin antagonist might also curb alcohol consumption in patients with early-onset alcoholism. By targeting specific serotonergic abnormalities, this drug offers a potential new path for managing complex, biologically predisposed addictive behaviors.

Ondansetron, a 5-HT3 receptor antagonist, was first patented in 1984 and gained medical approval in 1990. While it is widely recognized for its ability to block nausea and vomiting, its mechanism of action—specifically its interaction with serotonin receptors—has prompted investigations into its broader therapeutic potential. Unlike many other drugs, it does not affect dopamine or muscarinic receptors, which helps it avoid certain neurological side effects like akathisia.

A notable clinical trial conducted between 1995 and 1999 explored its impact on alcoholism. Researchers hypothesized that patients with early-onset alcoholism, who often exhibit distinct serotonergic abnormalities and antisocial traits, might respond to the drug. The results were promising: patients receiving ondansetron reported fewer drinks per day and a higher percentage of days abstinent compared to those on a placebo. Specifically, a dosage of 4 micrograms per kilogram twice daily showed significant efficacy in improving abstinence markers.

Despite its utility, the drug is not without risks. Clinical data indicates it can cause headaches and elevated liver enzymes, with a number-needed-to-harm of 36 and 31, respectively. Furthermore, there is a serious, though rare, risk of QT interval prolongation, which can lead to dangerous heart rhythms. While regulatory bodies have previously warned about potential serotonin syndrome when combined with other serotonergic medications, some experts argue these concerns lack sufficient evidence. As research continues, the drug remains a critical tool in clinical settings, balancing its proven anti-emetic benefits against its complex side-effect profile.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-ondansetron.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…